Currently, KRAS mutated NSCLC patients are classified into three clusters: One, including co-mutations in TP53 (KP), a second, carrying inactivating mutations in the tumor suppressor liver kinase b1 (LKB1) (KL), and a third, harboring bi-allelic deletions of two tumor suppressor genes, CDKN2A and CDKN2B (KC) [6]. Here, KRAS is linked to non-small cell lung carcinoma.